190 related articles for article (PubMed ID: 21665470)
41. Prolyl hydroxylase 2 deficiency limits proliferation of vascular smooth muscle cells by hypoxia-inducible factor-1{alpha}-dependent mechanisms.
Schultz K; Murthy V; Tatro JB; Beasley D
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L921-7. PubMed ID: 19304911
[TBL] [Abstract][Full Text] [Related]
42. Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation.
Takeda K; Fong GH
Hypertension; 2007 Jan; 49(1):178-84. PubMed ID: 17101841
[TBL] [Abstract][Full Text] [Related]
43. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
44. Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology.
Dao JH; Kurzeja RJ; Morachis JM; Veith H; Lewis J; Yu V; Tegley CM; Tagari P
Anal Biochem; 2009 Jan; 384(2):213-23. PubMed ID: 18952043
[TBL] [Abstract][Full Text] [Related]
45. Rapid degradation of hypoxia-inducible factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2.
Choi HJ; Song BJ; Gong YD; Gwak WJ; Soh Y
Br J Pharmacol; 2008 May; 154(1):114-25. PubMed ID: 18332861
[TBL] [Abstract][Full Text] [Related]
46. Disruption of dimerization and substrate phosphorylation inhibit factor inhibiting hypoxia-inducible factor (FIH) activity.
Lancaster DE; McNeill LA; McDonough MA; Aplin RT; Hewitson KS; Pugh CW; Ratcliffe PJ; Schofield CJ
Biochem J; 2004 Nov; 383(Pt. 3):429-37. PubMed ID: 15239670
[TBL] [Abstract][Full Text] [Related]
47. Assays to Study Hypoxia-Inducible Factor Prolyl Hydroxylase Domain 2 (PHD2), a Key Human Oxygen Sensing Protein.
Chan YY; Mbenza NM; Chan MC; Leung IKH
Methods Mol Biol; 2023; 2648():187-206. PubMed ID: 37039992
[TBL] [Abstract][Full Text] [Related]
48. HIF-1alpha peptide derivatives with modifications at the hydroxyproline residue as activators of HIF-1alpha.
Ahn DR; Kim SY; Lee MJ; Yang EG
Bioorg Med Chem Lett; 2009 Aug; 19(15):4403-5. PubMed ID: 19515556
[TBL] [Abstract][Full Text] [Related]
49. Substrate preference of the HIF-prolyl hydroxylase-2 (PHD2) and substrate-induced conformational change.
Pektas S; Knapp MJ
J Inorg Biochem; 2013 Sep; 126():55-60. PubMed ID: 23787140
[TBL] [Abstract][Full Text] [Related]
50. Prolyl hydroxylase inhibitor treatment confers whole-animal hypoxia tolerance.
Kasiganesan H; Sridharan V; Wright G
Acta Physiol (Oxf); 2007 Jun; 190(2):163-9. PubMed ID: 17394573
[TBL] [Abstract][Full Text] [Related]
51. Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase.
Nangaku M; Kojima I; Tanaka T; Ohse T; Kato H; Fujita T
Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):129-39. PubMed ID: 18221080
[TBL] [Abstract][Full Text] [Related]
52. β-N-oxalyl-L-α, β- diaminopropionic acid induces HRE expression by inhibiting HIF-prolyl hydroxylase-2 in normoxic conditions.
Eslavath RK; Sharma D; Bin Omar NAM; Chikati R; Teli MK; Rajanikant GK; Singh SS
Eur J Pharmacol; 2016 Nov; 791():405-411. PubMed ID: 27393459
[TBL] [Abstract][Full Text] [Related]
53. Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2).
McDonough MA; Li V; Flashman E; Chowdhury R; Mohr C; Liénard BM; Zondlo J; Oldham NJ; Clifton IJ; Lewis J; McNeill LA; Kurzeja RJ; Hewitson KS; Yang E; Jordan S; Syed RS; Schofield CJ
Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9814-9. PubMed ID: 16782814
[TBL] [Abstract][Full Text] [Related]
54. Evidence for the slow reaction of hypoxia-inducible factor prolyl hydroxylase 2 with oxygen.
Flashman E; Hoffart LM; Hamed RB; Bollinger JM; Krebs C; Schofield CJ
FEBS J; 2010 Oct; 277(19):4089-99. PubMed ID: 20840591
[TBL] [Abstract][Full Text] [Related]
55. Prolyl hydroxylase and hypoxia inducible factor: potential targets for cancer therapy.
Prabhu V; Guruvayoorappan C
Immunopharmacol Immunotoxicol; 2011 Sep; 33(3):568-75. PubMed ID: 21226555
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ.
Klotzsche-von Ameln A; Muschter A; Mamlouk S; Kalucka J; Prade I; Franke K; Rezaei M; Poitz DM; Breier G; Wielockx B
Cancer Res; 2011 May; 71(9):3306-16. PubMed ID: 21436457
[TBL] [Abstract][Full Text] [Related]
57. Increased chemoresistance induced by inhibition of HIF-prolyl-hydroxylase domain enzymes.
Brökers N; Le-Huu S; Vogel S; Hagos Y; Katschinski DM; Kleinschmidt M
Cancer Sci; 2010 Jan; 101(1):129-36. PubMed ID: 19817749
[TBL] [Abstract][Full Text] [Related]
58. Characterization of a second Arabidopsis thaliana prolyl 4-hydroxylase with distinct substrate specificity.
Tiainen P; Myllyharju J; Koivunen P
J Biol Chem; 2005 Jan; 280(2):1142-8. PubMed ID: 15528200
[TBL] [Abstract][Full Text] [Related]
59. Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal mice.
Duan LJ; Takeda K; Fong GH
Am J Pathol; 2011 Apr; 178(4):1881-90. PubMed ID: 21435465
[TBL] [Abstract][Full Text] [Related]
60. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay.
Ehrismann D; Flashman E; Genn DN; Mathioudakis N; Hewitson KS; Ratcliffe PJ; Schofield CJ
Biochem J; 2007 Jan; 401(1):227-34. PubMed ID: 16952279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
